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ABSTRACTISS
Fro
Gla
Un
Kin
(grOBJECTIVES The aim of this study was to mechanistically investigate associations among cigarette smoking, microvas-
cular pathology, and longer term health outcomes in patients with acute ST-segment elevation myocardial infarction (MI).
BACKGROUND The pathophysiology of myocardial reperfusion injury and prognosis in smokers with acute ST-segment
elevation MI is incompletely understood.
METHODS Patients were prospectively enrolled during emergency percutaneous coronary intervention. Microvascular
function in the culprit artery was measured invasively. Contrast-enhanced magnetic resonance imaging (1.5-T) was
performed 2 days and 6 months post-MI. Infarct size and microvascular obstruction were assessed using late gadolinium
enhancement imaging. Myocardial hemorrhage was assessed with T2* mapping. Pre-specified endpoints included: 1) all-
cause death or first heart failure hospitalization; and 2) cardiac death, nonfatal MI, or urgent coronary revascularization
(major adverse cardiovascular events). Binary logistic regression (odds ratio [OR] with 95% confidence interval [CI]) with
smoking status was used.
RESULTS In total, 324 patients with ST-segment elevation MI were enrolled (mean age 59 years, 73%men, 60% current
smokers). Current smokers were younger (age 55  11 years vs. 65  10 years, p < 0.001), with fewer patients with hy-
pertension (52  27% vs. 53  41%, p ¼ 0.007). Smokers had better TIMI (Thrombolysis In Myocardial Infarction) flow
grade ($2 vs. #1, p ¼ 0.024) and ST-segment resolution (none vs. partial vs. complete, p ¼ 0.010) post–percutaneous
coronary intervention. On day 1, smokers had higher circulating C-reactive protein, neutrophil, and monocyte levels. Two
days post-MI, smoking independently predicted infarct zone hemorrhage (OR: 2.76; 95%CI: 1.42 to 5.37; p¼0.003). After
a median follow-up period of 4 years, smoking independently predicted all-cause death or heart failure events (OR: 2.20;
95% CI: 1.07 to 4.54) and major adverse cardiovascular events (OR: 2.79; 95% CI: 2.30 to 5.99).
CONCLUSIONS Smoking is associated with enhanced inflammation acutely, infarct-zone hemorrhage subsequently,
and longer term adverse cardiac outcomes. Inflammation and irreversible myocardial hemorrhage post-MI
represent mechanistic drivers for adverse long-term prognosis in smokers. (Detection and Significance of Heart
Injury in ST Elevation Myocardial Infarction. [BHF MR-MI]; NCT02072850) (J Am Coll Cardiol Img 2019;12:993–1003)
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994C igarette smoking is persistentlycommon (1,2) and causal in thepathophysiology of acute myocar-
dial infarction (MI) (3–6). An apparent para-
doxical relationship has been described
between smoking and prognosis after acute
MI, with lower crude rates of adverse cardiac
events reported (7–12). Confounders,
including younger age and fewer vascular
risk factors, may explain the smoker’s
paradox (6–12). Moreover, the duration of
follow-up in many studies was #12 months,
and those studies with longer follow-up
identified smoking as an adverse prognostic
factor (13–15), implying the risk may operate
in the longer term post-MI.SEE PAGE 1004The pathophysiology of myocardial
reperfusion injury in smokers with acuteST-segment elevation MI (STEMI) is incompletely
understood. Higher epicardial coronary flow rates
after primary percutaneous coronary intervention
(PCI) have been reported in current smokers versus
nonsmokers (10). Studies of smoking and microvas-
cular pathology, using cardiac magnetic resonance
(CMR), have reported conflicting results (12,16), spe-
cifically pertaining to myocardial hemorrhage (an in-
dependent predictor of adverse outcome post-MI)
(17,18). The MRI method in previous studies was not
specific for detecting myocardial hemorrhage, and
information on health outcomes was limited to 12-
month follow-up (12) or was unavailable (16). T2*
mapping has emerged as a specific technique for
detecting myocardial hemorrhage post-MI (18), with
potential to resolve this controversy. Further insights
into the effect of smoking on myocardial reperfusion
injury could be provided by invasive microcirculatory
assessment in the culprit coronary artery, using index
of microcirculatory resistance (IMR), which is associ-
ated with infarct size, left ventricular (LV) pathology,
and health outcomes (19–24).
We aimed to prospectively investigate associations
between smoking,microvascular pathology and longer
term health outcomes in patients with acute STEMI.fellowship from the Scottish Funding Council. Drs. Mangion, M
fellowships FS/15/54/31639, FS/16/74/32573, and FS/12/62/29889,
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the manuscript. All other authors have reported that they have n
received February 12, 2018; revised manuscript received May 15We hypothesized that current smoking in patients
with acute STEMI would be associated with acute
microvascular dysfunction revealed by IMR and pro-
gressive hemorrhagic transformation within the infarct
zone revealed by T2* MRI 2 days post-MI. We also hy-
pothesized that smoking would be an independent
predictor of adverse longer term health outcomes.
METHODS
STUDY POPULATION. We performed a prospective
cohort study at a regional cardiac center from July
2011 to November 2012. Patients provided written
informed consent to undergo diagnostic guidewire-
based assessment after reperfusion, then MRI 2 days
and 6 months later and follow-up for health outcomes
in the longer term. Patients were eligible if they had
indications for primary PCI or thrombolysis for acute
STEMI (25). Exclusion criteria were standard contra-
indications to MRI. Current smoking status was
defined as use of $100 cigarettes by a patient in his or
her lifetime who currently routinely smoked ciga-
rettes (26). Primary PCI and secondary prevention
measures, including cardiac rehabilitation with risk
factor management, were implemented according
to contemporary guidelines (25). The study
was approved by the National Research Ethics Service
(10-S0703-28). The ClinicalTrials.gov identifier is
NCT02072850.
IMR IN THE CULPRIT CORONARY ARTERY. A coro-
nary guidewire with a pressure and temperature
sensor (St. Jude Medical, St. Paul, Minnesota) was
used to measure IMR in the culprit coronary artery at
the end of primary or rescue PCI. The guidewire was
calibrated outside the body, equalized with aortic
pressure at the ostium of the guide catheter, and then
advanced to the distal third of the culprit artery. IMR,
an invasive measure of microvascular resistance, is
defined as distal coronary pressure multiplied by
mean transit time of a bolus of saline at room tem-
perature, during maximal coronary hyperemia (23).
Hyperemia was induced by 140 mg/kg/min of intra-
venous adenosine preceded by an intracoronary
bolus of 200 mg of nitrate. We previously found IMR to
be highly repeatable when assessed by duplicateaznyczka, and Welsh are supported by British Heart
respectively. Siemens Healthcare provided work-in-
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FIGURE 1 Smoking and Myocardial Hemorrhage After Acute ST-Segment Elevation Myocardial Infarction
A B C D
E F G H
Current smoker (A to D) and nonsmoker (E to H) who underwent primary percutaneous coronary intervention (PCI) for lateral ST-segment elevation myocardial
infarction. Both had TIMI (Thrombolysis in Myocardial Infarction) flow grade 3 post-PCI. Antithrombotic therapies, including aspirin, clopidogrel, and unfractionated
heparin, were similar for both patients. Magnetic resonance imaging (MRI) was performed 2 days and 6 months later. (A to D) Imaging from a 58-year-old male current
smoker. Symptom-to-balloon time was 8.5 h. Angiography revealed a proximally occluded circumflex coronary artery (yellow arrow, A). Two days later, myocardial
hemorrhage was revealed by T2* mapping (white arrow, C). Late gadolinium enhancement revealed transmural infarction of the lateral left ventricular (LV) wall
(white arrows, D) associated with microvascular obstruction (MVO) (yellow arrow, D). Baseline infarct size was 32.3%, LV ejection fraction 55%, and LV end-diastolic
volume indexed to body surface area (LVEDVi) 83.8 ml/m2. Six months later, infarct size was 31.2% and LVEDVi 84.8ml/m2, consistent with adverse remodeling.
(E to H) Imaging from a 48-year-old male nonsmoker. Symptom-to-balloon time was 9.3 h. Angiography revealed a proximally occluded circumflex coronary artery
(yellow arrow, E). Two days later, there was no evidence of myocardial hemorrhage (G) or MVO within the infarct zone (H) on MRI. Baseline infarct size was 25.3%,
LV ejection fraction 51%, and LVEDVi 78.4 ml/m2. Six months later, infarct size was 15.2% and LVEDVi 72.7 ml/m2.
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995measurements 5 min apart in 12 consecutive patients
with STEMI at the end of PCI (20).
ELECTROCARDIOGRAPHY. Twelve-lead electrocar-
diograms were obtained before coronary reperfusion
and 60 min afterward. ST-segment resolution
assessed 60 min after reperfusion was compared with
the baseline electrocardiogram before reperfusion
and was expressed as complete (70%), incomplete
(30% to <70%), or none (30%).
CORONARY ANGIOGRAPHIC ACQUISITION AND
ANALYSES. Coronary angiograms were acquired
during usual care with a cardiac catheter laboratory
radiograph (Innova, GE Healthcare, Little Chalfont,
United Kingdom) and information technology equip-
ment (Centricity, GE Healthcare). Angiograms were
analyzed by trained observers (J.C., V.T.Y.M.) who
were blinded to other clinical and MRI data. TIMI
(Thrombolysis In Myocardial Infarction) coronary
flow grade (27) and frame count (28) were assessed atinitial angiography and at the end of the procedure.
TIMI myocardial perfusion grade (29) was assessed at
the end of the procedure (Supplemental Appendix).
LABORATORY ANALYSES. The blood samples and
analyses of hematology and biochemistry, including
serum troponin T, C-reactive protein, and N-terminal
pro–B-type natriuretic peptide (NT-proBNP) are
described in the Supplemental Appendix.
CARDIAC MRI. MRI was used to provide reference
data on LV function, pathology, and surrogate out-
comes (Figure 1). MRI was performed using a Siemens
MAGNETOM Avanto (Siemens Healthcare, Erlangen,
Germany) 1.5-T scanner with a 12-element phased-
array cardiac surface coil. The imaging protocol
(18,21,22,30) (Supplemental Appendix) included cine
MRI with steady-state free precession, T2 mapping
(31,32), T2* mapping (18), and delayed-enhancement
phase-sensitive inversion recovery pulse sequences
TABLE 1 Clinical and Angiographic Characteristics of 324 Patients With ST-Segment
Elevation Myocardial Infarction Categorized According to Smoking Status at Initial
Presentation
All Patients
(N ¼ 324)
Nonsmokers
(n ¼ 128 [40%])
Current Smokers
(n ¼ 196 [60%]) p Value
Age, yrs 59  12 65  10 55  11 <0.001 (t)
Male 237 (73) 98 (77) 139 (71) 0.305
BMI, kg/m2 28.8  4.8 29.1  4.6 28.6  4.8 0.346 (t)
Hypertension 105 (32) 53 (41) 52 (27) 0.007
Hypercholesterolemia 94 (29) 44 (34) 50 (26) 0.103
Diabetes mellitus* 34 (11) 14 (11) 20 (10) 0.854
Previous myocardial
infarction
25 (8) 11 (9) 14 (7) 0.673
Previous PCI 18 (6) 8 (6) 10 (5) 0.805
Presenting characteristics
Heart rate, beats/min 78  17 77  16 78  18 0.518 (t)
Systolic blood pressure,
mm Hg
135  25 137  23 134  25 0.264 (t)
Symptom-to-reperfusion
time, min
174 (120–315) 176 (120–307) 171 (122–324) 0.984 (MW)
Killip class at
presentation†
I 233 (72) 100 (78) 133 (68)
II 68 (21) 21 (16) 47 (24) 0.138
III/IV 23 (7) 7 (6) 16 (8)
ST-segment resolution
post-PCI
Complete, $70% 148 (46) 46 (36) 102 (52)
Incomplete, 30%
to <70%
127 (39) 57 (45) 70 (36) 0.010
None, #30% 48 (15) 25 (20) 23 (12)
Reperfusion strategy
Primary PCI 302 (93) 122 (95) 180 (92)
Rescue PCI (failed
thrombolysis)
14 (4) 4 (3) 10 (5) 0.497
Successful thrombolysis 8 (3) 2 (2) 6 (3)
Coronary angiography
Number of diseased
arteries‡
1 174 (54) 64 (50) 110 (56)
2 99 (31) 41 (32) 58 (30) 0.635
3 45 (14) 21 (16) 24 (12)
Continued on the next page
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and also included different slice orientations to
enhance diagnostic confidence.
IMAGING ANALYSES. The MRI analyses are
described in detail in the Supplemental Appendix.
The results of infarct characteristics are reported for
the whole of the left ventricle.
INFARCT SIZE, MICROVASCULAR OBSTRUCTION,
AND MYOCARDIAL HEMORRHAGE. The presence of
acute infarction was established on the basis of ab-
normalities in cine wall motion, rest first-pass
myocardial perfusion, and delayed-enhancement
imaging in 2 imaging planes. The myocardial mass
of late gadolinium (grams) was quantified using
computer-assisted planimetry, and the territory ofinfarction was delineated using a signal intensity
threshold of >5 SDs above a remote reference region
and expressed as a percentage of total LV mass
(18,21,22,30,34).
Microvascular obstruction (MVO) was defined as a
dark zone on late gadolinium enhancement imaging
1, 3, and 5 min post–contrast injection that remained
present within an area of late gadolinium enhance-
ment at 15 min. On the T2* MRI maps, a region of
reduced signal intensity within the infarcted area
with a T2* value of <20 ms (18,35) was considered to
confirm the presence of myocardial hemorrhage.
MYOCARDIAL EDEMA AND SALVAGE. The extent of
myocardial edemawas defined as LVmyocardiumwith
pixel values >2 SDs from remote myocardium (36–38).
Myocardial salvage was calculated by subtraction of
percentage infarct size from percentage area at risk, as
reflected by the extent of edema (20,36–39). The
myocardial salvage index was calculated by dividing
the myocardial salvage area by the initial area at risk.
LV REMODELING. An increase of $20% in LV end-
diastolic volume at 6 months from baseline was
taken to reflect adverse LV remodeling (40).
PRE-SPECIFIED HEALTH OUTCOMES. The primary
composite outcome was all-cause death or first heart
failure event following the initial hospitalization. The
second composite outcome was major adverse car-
diovascular events (MACE) including cardiac death,
nonfatal MI, and urgent coronary revascularization.
These outcomes were independently assessed
by cardiologists blind to the baseline findings
(Supplemental Appendix) (41).
STATISTICAL ANALYSES. The sample size calcula-
tion and statistical methods are described in the
Supplemental Appendix. Differences in continuous
variables between groups were assessed using the
Student t-test or analysis of variance for parametric
data and the Mann-Whitney U test or Kruskal-Wallis
H test for nonparametric data. Differences in cate-
gorical variables were assessed using a chi-square or
Fisher exact test. Univariate and multivariate asso-
ciations were assessed using binary logistic regres-
sion or linear regression as appropriate. Binary
logistic models were compared using Harrel’s C sta-
tistic. Logistic regression (odds ratio [OR] and 95%
confidence interval [CI]) was used to identify clinical
predictors (patient characteristics and MRI findings)
of all-cause death or heart failure events. Statistical
analyses were performed using R version 2.15.1 (R
Foundation for Statistical Computing, Vienna,
Austria) or SAS version 9.3 (SAS Institute, Cary,
North Carolina). A p value <0.05 represented sta-
tistical significance.
TABLE 1 Continued
All Patients
(N ¼ 324)
Nonsmokers
(n ¼ 128 [40%])
Current Smokers
(n ¼ 196 [60%]) p Value
Culprit artery
LM 6 (2) 2 (2) 4 (2)
LAD 121 (37) 50 (39) 71 (36)
LCx 59 (18) 15 (12) 44 (22) 0.045
RCA 144 (44) 63 (49) 81 (41)
TIMI coronary flow grade
pre-PCI
0/1 236 (73) 93 (73) 143 (73)
2/3 88 (27) 35 (27) 53 (27) 1.000
TIMI coronary flow grade
post-PCI
0/1 4 (1) 4 (3) 0 (0)
2/3 320 (99) 124 (97) 196 (100) 0.024
TIMI frame count
post-PCI
15.9 (10.0-24.3) 15.7 (10.0–24.0) 16.0 (9.9–24.7) 0.631 (MW)
TIMI blush grade post-PCI
0 70 (23) 26 (21) 44 (24)
1 17 (6) 7 (6) 10 (5) 0.901
2 157 (51) 65 (53) 92 (49)
3 65 (21) 24 (20) 41 (22)
Culprit lesion, percentage
residual stenosis
12.4 (5.4) 12.4 (5.6) 12.4 (5.2) 0.997 (t)
Index of microvascular
resistance§
1.6 (1.1–2.1) 27 (16–47) 22 (15–41) 0.062
Aspiration thrombectomy 236 (73) 92 (72) 144 (74) 0.799
Glycoprotein IIb/IIIa
inhibitor
297 (92) 118 (92) 179 (91) 0.840
Medical therapy at
discharge
ACE inhibitor or ARB 320 (99) 127 (98) 193 (99) 0.579
Beta-blocker 308 (95) 121 (95) 187 (95) 0.795
Statin 324 (100) 128 (100) 196 (100) 1.00
Antiplatelet therapy
Aspirin 323 (99.7) 128 (100.0) 195 (99.5) 1.00
Clopidogrel 321 (99.1) 127 (99.2) 194 (99.0) 1.00
Initial blood results on
admission
Creatinine, mg/l 77.8  18.9 83.2  21.4 74.3  16.2 <0.001 (t)
C-reactive protein, mg/l§ 4 (2–7) 3 (2–7) 4 (2–8) 0.035 (MW)
Interleukin-6, pg/ml 6.8 (4.4–10.8) 7.8 (4.6–12.3) 6.4 (4.4–10.6) 0.531 (MW)
Neutrophil count, 106/l 9.1 (7.2–11.6) 8.3 (6.7–10.4) 9.6 (7.9–12.1) <0.001 (MW)
Monocyte count, 106/l 0.8 (0.6–1.0) 0.7 (0.6–0.9) 0.9 (0.7–1.1) <0.001 (MW)
NT-proBNP, pg/l 864
(345–1,637)
1,040
(529–1,860)
646
(300–1,388)
0.022 (MW)
Troponin T, ng/l§ 1,710
(110–5,099)
1,496
(82–4,410)
1,945
(178–5,133)
0.265 (MW)
Values are mean  SD, n (%), or median (interquartile range). The p values were obtained from Student t-tests
(t), Mann-Whitney U tests (MW), or Fisher exact tests. TIMI flow grades pre- and post-PCI were grouped as 0/1
versus 2/3 for this analysis. *Diabetes mellitus was defined as a history of diet-controlled or treated diabetes.
†Killip classification of heart failure after acute myocardial infarction: class I, no heart failure; class II, pulmonary
rales or crepitations, a third heart sound, and elevated jugular venous pressure; class III, acute pulmonary edema;
class IV, cardiogenic shock. ‡Multivessel coronary artery disease was defined according to the number of stenoses
of at least 50% of the reference vessel diameter, by visual assessment, and whether or not there was left main
stem involvement. §C-reactive protein was available in 316 subjects, and troponin T was available in 313 subjects.
IMR was available in 283 subjects.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; LAD ¼
left anterior descending coronary artery; LCx ¼ left circumflex coronary artery; LM ¼ left main coronary artery;
NT-proBNP ¼ N-terminal pro–brain natriuretic peptide; PCI ¼ percutaneous coronary intervention; RCA ¼ right
coronary artery; TIMI ¼ Thrombolysis In Myocardial Infarction.
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997RESULTS
PATIENT CHARACTERISTICS. Of 372 consecutive pa-
tients with acute STEMI who were assessed for eligi-
bility, 324 (87%) (mean age 59  12 years, 237 [73%]
men, 196 [60%] smokers) were enrolled (Table 1,
Figure 2). Reasons for not being enrolled are detailed in
Figure 2. Comparedwith nonsmokers, current smokers
were younger and had fewer cardiovascular risk fac-
tors (Table 1). The distribution of the infarct-related
artery differed between smokers and nonsmokers,
whereas the biochemical size of infarction was similar.
CULPRIT ARTERY BLOOD FLOW AND REPERFUSION
INJURY. At the end of the emergency PCI procedure,
TIMI flow grade in the culprit coronary artery was
higher ($2 vs. #1) in smokers than nonsmokers
(p ¼ 0.024), whereas TIMI blush grade and frame
count were similar between groups. At 60 min post-
reperfusion, ST-segment resolution was achieved
more often in smokers than nonsmokers (p ¼ 0.01).
IMR tended to be lower in smokers (22 [interquartile
range: 15 to 41] vs. 27 [interquartile range: 16 to 47],
p ¼ 0.062), although the difference was not statisti-
cally significant.
SYSTEMIC INFLAMMATION AND NT-proBNP. On day 1,
circulating C-reactive protein, neutrophil, and mono-
cyte levels were higher in current smokers, whereas
NT-proBNP concentrations were lower (Table 1).
CARDIAC MRI FINDINGS. A total of 324 patients un-
derwent MRI 2.1  1.8 days after hospitalization, and
295 patients (91%) underwent follow-up MRI at 6
months (Table 2, Figure 2). Case examples are shown
in Figure 1.
LV ejection fraction and mass in a subgroup of 10
randomly chosen patients were independently
measured by 2 observers. The intraclass correlation
coefficient for reliability of LV ejection fraction
was 0.997 (95% CI: 0.963 to 0.999; p < 0.001). The
mean absolute difference between measures was
0.99 ml/m2, and the root mean square error was 0.93.
The intraclass correlation coefficient for reliability of
LV mass was 0.997 (95% CI: 0.982 to 0.999; p < 0.001).
The mean absolute difference between measures was
2.83 g/m2, and the root mean square error was 3.51.
Bland-Altman plots showed no evidence of bias.
Baseline infarct size, MVO, and LV function were
similar between groups, whereas LV mass was greater
in male smokers than male nonsmokers, consistent
with the age difference between the groups (Table 1).
T2* MRI for myocardial hemorrhage was performed
in 286 patients (88%), and 245 (85%) had evaluable
T2* maps. The percentage of patients with myocardial
FIGURE 2 Flow Diagram
Patients with acute STEMI assessed
for eligibility (n = 372)
Enrollment with informed
consent
No CMR (n = 48)
• Claustrophobia (n = 22)
• Death (n = 2)
• Logistical (e.g. MRI service) (n = 18)
• Contraindication to MRI (n = 3)
• Refusal (n = 3)
CMR (Day 2) (n = 324)
CMR and intra-coronary sensor assessment of
microvascular resistance (n = 289)
CMR with a T2* map at
baseline (n = 286)
Analysis
Follow-Up
CMR scan 6 months post-STEMI (n = 300)
Health outcomes in longer term (n = 324)
• T2* maps non-evaluable due to motion
   artifact (n = 41)
No CMR at 6 months follow-up (n = 19)
• Death (n = 3)
• Refused (n = 21)
CMR with an evaluable T2*
map at baseline (n = 245)
CMR performed but without T2* mapping
for myocardial hemorrhage (n = 38):
     • T2* map pulse sequence not installed
        (n = 24) (the MRI pulse sequence
        became available after patient #24)
     • Intolerance of the scan (n = 14)
Consolidated Standards of Reporting Trials flow diagram of the study. CMR ¼ cardiac magnetic resonance; MRI ¼ magnetic resonance im-
aging; STEMI ¼ ST-segment elevation myocardial infarction.
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998hemorrhage was higher in smokers (46%) than in
nonsmokers (34%), although this difference was not
significant (Table 2).
MULTIVARIATE ASSOCIATIONS FOR CURRENT
SMOKING WITH MICROVASCULAR INFARCT
PATHOLOGY REVEALED BY MRI. Microvascular
obstruction. In a binary logistic regression model with
baseline characteristics, smoking was independently
associated with MVO (OR: 1.72; 95% CI: 1.02 to 2.90;
p ¼ 0.041) (Supplemental Appendix), but this associ-
ation became nonsignificant when infarct size (re-
flected by peak troponin I concentration) was
included in the model (p ¼ 0.11).Myocardial hemorrhage. Smoking was an independent
associate of myocardial hemorrhage (OR: 2.55;
95% CI: 1.39 to 4.70; p ¼ 0.003), along with male sex,
TIMI coronary flow grade at the end of PCI, and
ST-segment resolution (Table 3). Unlike MVO, this
association was independent of infarct size, as
reflected by peak troponin I (OR: 2.76; 95% CI: 1.42 to
5.37; p ¼ 0.003).
SMOKING AND LV OUTCOMES AT 6 MONTHS. LV
end-diastolic volume and function. A history of smoking
was a multivariate associate of LV end-diastolic
volume at 6 months (b ¼ 4.85; 95% CI: 0.59 to 10.28;
p ¼ 0.08), but the association was not statistically
TABLE 2 Cardiac Magnetic Resonance Imaging Findings at 2 Days and 6 Months Post-
Reperfusion in 324 Patients With ST-Segment Elevation Myocardial Infarction Categorized
According to Smoking Status
All Patients
(n ¼ 324)
Nonsmokers
(n ¼ 128
[40%])
Current
Smokers
(n ¼ 196
[60%]) p Value
CMR findings 2 days post-MI
(n ¼ 324)
LV ejection fraction, % 55  10 55  10 55  10 0.802 (t)
LVEDV, ml
Men 161  33 156  28 165  36 0.051 (t)
Women 125  25 122  27 127  24 0.423 (t)
LVESV, ml
Men 75  27 72  24 78  28 0.117 (t)
Women 55  18 55  19 55  18 0.856 (t)
LV mass, g
Men 145  33 139  27 149  36 0.016 (t)
Women 99  23 96  25 100  22 0.711 (t)
Edema and infarct
characteristics
Myocardial edema,
percentage LV mass
32  12 32  12 32  12 0.663 (t)
T2 relaxation times (ms) in
regions of interest
Infarct zone 62.9  5.1 63.3  5.0 62.6  5.2 0.224 (t)
Infarct core 53.9  4.8 54.1  4.7 53.7  5.0 0.570 (t)
Remote zone T2 49.7  2.1 49.5  2.0 49.9  2.1 0.176 (t)
Infarct size, percentage
LV mass
16  7, 27 19  7, 27 15  7, 28 0.752 (MW)
Myocardial salvage index,
percentage of LV mass
63  24 64  23 62  25 0.678 (t)
Late microvascular
obstruction
164 (51) 62 (48) 102 (52) 0.570
Late microvascular
obstruction, percentage
LV mass
0.2 (0.0 to 3.5) 0.0 (0.0 to 3.3) 0.3 (0.0 to 3.8) 0.572 (MW)
Myocardial hemorrhage 101 (41) 31 (34) 70 (46) 0.081
CMR findings 6 months post-MI
(n ¼ 295)
LV ejection fraction at
6 months, %
63 (57 to 69) 63 (57 to 68) 63 (56 to 69) 0.780
(MW)
LVESV at 6 months, ml
Men 62 (44 to 79) 60 (42 to 75) 64 (48 to 82) 0.121 (MW)
Women 43 (33 to 58) 49 (39 to 60) 41 (33 to 54) 0.119 (MW)
Change in LVEDV at 6 months
from baseline, ml
Men 7 (7 to 21) 7 (8 to 18) 6 (7 to 22) 0.687 (MW)
Women 1 (12 to 9) 3 (11 to 9) 2 (13 to 10) 0.639 (MW)
Values are mean  SD, n (%), or median (interquartile range). Area at risk was measured using T2 mapping. The p
values were obtained using Student t-tests (t), Mann-Whitney U tests (MW), or Fisher exact tests. LV ejection
fraction was missing in 29 subjects at follow-up. LVEDV at follow-up was missing in 16 men and 8 women. T2*
imaging for myocardial hemorrhage was available in 245 subjects.
CMR ¼ cardiac magnetic resonance; LV ¼ left ventricular; LVEDV ¼ LV end-diastolic volume; LVESV ¼ left
ventricular end-systolic volume; MI ¼ myocardial infarction; T1 ¼ myocardial longitudinal relaxation time.
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999significant. Smoking was not associated with either
adverse LV remodeling or LV ejection fraction at 6
months (p ¼ 0.26).
MICROVASCULAR DYSFUNCTION AND LONGER
TERM HEALTH OUTCOMES. All (n ¼ 324) patients had
long-term follow-up data completed. The median
duration of follow-up was 4 years (post-discharge
censor duration range 3.9 to 4.9 years). Forty-seven
patients (15%) died or experienced a first heart fail-
ure event during the index hospitalization or post-
discharge. These events included 4 cardiovascular
deaths, 11 noncardiovascular deaths, 2 deaths of un-
determined cause, and 30 episodes of heart failure
(Killip class $III [n ¼ 28] or defibrillator implantation
[n ¼ 2]). Twenty-three patients (7%) died or experi-
enced a first heart failure hospitalization post-
discharge. Smoking was a multivariate associate of
all-cause death or heart failure events (n ¼ 32 in
smokers, n ¼ 15 in nonsmokers; OR: 2.20; 95% CI: 1.07
to 4.54; p ¼ 0.032) (Table 4).
Forty-nine patients (15%) experienced MACE
during the index hospitalization or post-discharge.
These events included 3 cardiovascular deaths, 4
episodes of STEMI, 13 episodes of non-STEMI, and
29 episodes of heart failure (Killip class $III [n ¼ 27]
or defibrillator implantation [n ¼ 2]). One patient
experienced a STEMI and was censored before
experiencing an episode of heart failure, hence there
were 30 heart failure events for all-cause death or
heart failure and 29 for MACE during a median of
4 years of follow-up (n ¼ 35 in smokers, n ¼ 14
in nonsmokers; OR: 2.79; 95% CI: 2.30 to 5.99;
p ¼ 0.008) (Table 4).
DISCUSSION
We have undertaken a large prospective study of
smoking status, infarct pathophysiology, and long-
term prognosis in patients with acute STEMI. We
found that current smoking is associated with a
more favorable cardiovascular risk profile at initial
presentation (e.g. younger age, fewer patients
with hypertension, and higher coronary flow grades
at the end of primary PCI), reflecting better proce-
dural outcomes. Contrary to our hypothesis, acute
reperfusion injury (revealed invasively by IMR and
noninvasively by ST-segment resolution on electro-
cardiography) was less pronounced in smokers,
suggesting initial favorable findings associated with
smoking. Subsequent assessments revealed a less
favorable risk profile in smokers in the days following
the acute event, including more pronounced systemic
inflammation on day 1. In multivariate analyses,
smoking was independently associated with a 3-foldincreased likelihood of myocardial hemorrhage on
day 2, independent of infarct size. Finally, current
smoking was independently associated with a 2-fold
increased risk for all-cause death or heart failure
during a median of 4 years of follow-up (similar
associations were observed for MACE).
TABLE 3 Multivariate Associations Between Clinical Characteristics,
Including Smoking, in 244 Patients With Acute ST-Segment Elevation
Myocardial Infarction and Evaluable T2* Mapping for Myocardial Hemorrhage
Binary Logistic Regression Odds Ratio (95% CI) p Value
Univariate models
TIMI coronary flow grade 2/3 pre-PCI 0.26 (0.13–0.51) <0.001
Peak troponin I, ng/l 1.00 (1.00–1.00) <0.001
ST-segment elevation resolution post-PCI
None, #30% 3.37 (1.56–7.26) 0.002
Incomplete, 30% to <70% 2.31 (1.30–4.10) 0.004
Killip class II 1.59 (0.87–2.93) 0.14
Killip class III/IV 30.37 (3.93–234.69) 0.001
Male 1.97 (1.04–3.71) 0.037
Current cigarette smoker 1.66 (0.97–2.84) 0.064
History of hypertension 1.50 (0.87–2.59) 0.143
Multivariate model
TIMI coronary flow grade 2/3 pre-PCI 0.25 (0.12–0.51) <0.001
Male 2.67 (1.33–5.38) 0.006
Current cigarette smoker 2.55 (1.39–4.70) 0.003
ST-segment elevation resolution post-PCI
Incomplete, 30% to <70% 2.44 (1.31–4.53) 0.005
None, #30% 3.90 (1.69–9.02) 0.001
History of hypertension 1.81 (0.98–3.34) 0.059
Harrel’s C statistic 0.746
The univariate associations for the patient characteristics at initial presentation and myocardial
hemorrhage include those listed in the table and age (1 year), p¼ 0.74; body mass index (1 kg/m2),
p¼0.85; history of hypertension, p¼0.14; hypercholesterolemia, p¼0.39; prior angina, p¼0.39;
previousMI, p¼0.61; diabetes, p¼0.16; heart rate (1beat/min), p¼0.20; and sustainedventricular
arrhythmia, p ¼ 0.66. All of the univariate characteristics were used to determine the multivariate
model. Amanual backward selection approachwas used to establish the final model using a p value
threshold for exclusion of 0.10. When smoking is removed from the model, the C statistic drops
from 0.746 to 0.712.
CI ¼ confidence interval; other abbreviations as in Table 1.
TABLE 4 Relationships for Smoking Status in 324 Subjects and All-Cause
Death or First Hospitalization for Heart Failure or Major Adverse Cardiovas-
cular Events During or After the Index Hospitalization Obtained Using Logistic
Regression
Associations Odds Ratio (95% CI) p Value
All-cause death or first hospitalization for
heart failure
History of myocardial infarction 6.19 (2.40–15.95) <0.001
History of hypertension 2.53 (1.28–4.98) 0.007
ST-segment elevation resolution post-PCI
Incomplete, 30% to <70% 3.41 (1.54–7.56) 0.003
None, #30% 4.13 (1.55–11.06) 0.005
Current cigarette smoker 2.20 (1.07–4.54) 0.032
MACE
History of myocardial infarction 5.16 (1.87–14.25) 0.002
Ventricular arrhythmia 5.11 (1.68–15.50) 0.004
TIMI coronary flow grade 2/3 pre-PCI 0.20 (0.07–0.60) 0.004
Current cigarette smoker 2.79 (2.30–5.99) 0.008
ST-segment elevation resolution post-PCI
Incomplete, 30% to <70% 2.86 (1.27–6.46) 0.011
None, #30% 7.28 (2.78–19.02) <0.001
The median duration of follow-up was 4 years (post-discharge censor duration range: 1,236 to
1,801 days). Forty-seven patients (15%) died or experienced a first heart failure event during the
index hospitalization or post-discharge. Forty-nine patients (15%) experienced MACE.
MACE ¼ major adverse cardiovascular event(s); other abbreviations as in Table 1.
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1000Despite their younger age, the longer-term prog-
nosis of smokers is worse than that of nonsmokers,
including for cardiac events. Our findings should
dispel the false notion of any favorable associations
between smoking and prognosis after acute STEMI.
NEW PATHOPHYSIOLOGICAL INSIGHTS INTO THE
APPARENT SMOKER’S PARADOX IN ACUTE
STEMI. Consistent with prior studies (4,7–12,16), we
found that smoking was crudely associated with more
favorable presenting characteristics (e.g., younger
age) and procedure outcomes. In contrast to prior
reports (7–12), smoking was independently associated
with increased risk for adverse longer term health
outcomes.
Our results indicate distinct phases in the early
course of MI in smokers (Figure 3). We observed a
reverse paradox in that smoking was associated with
less reperfusion injury acutely, as revealed by angi-
ography, electrocardiography, and invasive microcir-
culatory measurements using IMR, but 2 days later,
myocardial hemorrhage was more pronounced
(Figure 1), even after adjustment for confounding
covariates.
We postulate the following explanations for these
findings. First, smokers were younger, they had fewer
risk factors for microvascular dysfunction (4,7–12),
and they presented with anterior MI less often. These
factors most likely explain why smokers had less
reperfusion injury acutely. Given the harmful effects
of smoking on vascular health (4), the reperfused
microvessels in smokers may have reduced repair
potential and thus greater susceptibility to progres-
sive degradation within the infarct core in the days
after reperfusion. Second, in a serial imaging study,
we found that myocardial hemorrhage was preceded
by MVO (18), as MVO is an upstream event that
may resolve. Our results indicate that the progression
to infarct zone hemorrhage, rather than recovery
without hemorrhage, was more likely in smokers than
nonsmokers. Even after accounting for infarct size,
the association between smoking and infarct zone
hemorrhage persisted, unlike for MVO. This obser-
vation is prognostically relevant because myocardial
hemorrhage reflects irreversible tissue damage
(17,18). A recent study that described the independent
prognostic importance of MVO post-MI did not
include information on myocardial hemorrhage (42).
Using contemporary, multiparametric cardiac mag-
netic resonance using T2* mapping, we have found
that myocardial hemorrhage is a much stronger
determinant of adverse prognosis than MVO (18).
The lack of an association between smoking and
myocardial hemorrhage in prior studies (12) may have
been related to the use of dark-blood T2-weighted
FIGURE 3 Smoking and Microvascular Pathology After ST-Segment Elevation
Myocardial Infarction
Pathophysiology
Acute STEMI
Cigarette
smoking
Lifestyle Infarct Pathology
MRI post-MI
Prognosis
Younger age
Less CAD
Successful PCI
↑ MACE
X2 ↑ MVO
Infarct size ⇔ ↑ Heart
failure
↑ Death↑ Systemic inflammation
↓ Microvascular injury
acutely
Microvasculature:
↓ healing and repair
↑ susceptibility
   degradation
X3 ↑ IMH
Schematic of the pathophysiology of cigarette smoking, infarct pathology, and prognosis
post–acute ST-segment elevation myocardial infarction (STEMI). The results indicate that
smoking is associated with accelerated vascular risk. Despite a typically successful
outcome after primary percutaneous coronary intervention (PCI), microvascular pa-
thology within the infarct zone (MVO [microvascular obstruction] and myocardial
hemorrhage) is more likely, which increases the long-term risk. CAD ¼ coronary artery
disease; IMH ¼ intramyocardial hemorrhage; MACE ¼ major adverse cardiac events.
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1001MRI, which has limited diagnostic accuracy (38) when
considered against the more sensitive and specific
T2* mapping (18,35). Third, current smoking was
associated with systemic inflammation (Table 1),
which is also independently associated with micro-
vascular pathology (18) and prognosis (43). Inflam-
mation may serve as a mechanistic link mediating
progressive vascular injury and reduced repair
potential within the infarct zone, leading in turn to
myocardial hemorrhage. Some confounding observa-
tions included lower circulating NT-proBNP concen-
trations in smokers than in nonsmokers. This may
be explained by the fact that compared with
nonsmokers, current smokers were younger and
had better renal function, and anterior MI occurred
less often. Circulating concentrations of troponin
are paradoxically lower in current smokers from
the general population. The mechanisms of this
observation remain to be elucidated (44).
RELEVANCE TO PUBLIC HEALTH. Our study has
important public health implications. We observed
that during longer term follow-up, current smoking
prior to acute STEMI is a multivariate associate of all-
cause death or heart failure, providing new insights
into the smoker’s paradox. The association between
microvascular pathology and smoking provides a
mechanistic explanation for the adverse risk. Because
previous MI is a strong predictor of recurrent MI, ef-
forts from health care professionals to help patients
achieve smoking cessation are all the more relevant.
STUDY LIMITATIONS. We performed a single-center
natural history study and enrolled a high proportion
(w90%) of screened patients. The reasons in the
majority of those patients not enrolled (Figure 2)
related to contraindications to MRI (e.g., claustro-
phobia) and logistics, rather than the severity of MI,
implying that the cohort is representative of an all-
comers STEMI population. Smoking status was self-
reported. We did not gather information on the
duration, frequency, or type of cigarette smoking, nor
did we gather information on smoking status during
follow-up. All smokers were referred for smoking
cessation therapy as part of cardiac rehabilitation.
The mean LV ejection fraction (55%) probably reflects
the comparatively short ischemic time overall (the
median door-to-balloon time in our hospital is 21
min). The study population included 21 patients
initially treated with thrombolysis, and 14 of these
patients underwent rescue PCI. The main results of
our study were unchanged when these patients were
removed. Cigarette smoking post-MI may have influ-
enced the prognostic associations between a history
of smoking before the initial MI and adversecardiovascular events in the longer term. Smoking
status was not reevaluated at 6 months, which rep-
resents a limitation of the study design. The multi-
variate model (Table 3) could be considered as
overfitted by traditional standards. No adjustment
was made for skewed variables in the multivariate
analyses. Our analysis does not permit inference on
causality, and further studies are warranted.
CONCLUSIONS
Current smokers presenting with acute STEMI are
nearly 10 years younger than nonsmokers, consistent
with an accelerated vascular risk. Current smoking is
independently associated with irreversible infarct
zone hemorrhage and systemic inflammation
following acute STEMI and worse longer term health
outcomes.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Our
study provides new insights into the smoker’s paradox.
We have shown that cigarette smoking is independently
associated with irreversible infarct zone hemorrhage,
systemic inflammation following acute STEMI, and worse
longer term health outcomes. Our results should dispel
the false notion of any favorable associations between
smoking and prognosis after acute STEMI. Because pre-
vious MI is a strong predictor of recurrent MI, efforts from
health care professionals to help patients achieve smok-
ing cessation are all the more relevant.
TRANSLATIONAL OUTLOOK: Future studies are
needed to confirm the findings using biochemical indica-
tors of smoking status and using information on the
duration, frequency, or type of cigarette smoking, as well
as smoking status during follow-up.
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